Joanne Pike

Innovating Hope: Charting the New Era of Alzheimer's & Other Dementias | Future of Health Summit

Allison Aubrey, Kris Engskov, Jessie Fahrbach, Howard Fillit, Richard Isaacson, Joanne Pike, Chris Inskov

Recent FDA approvals of amyloid-targeting drugs and advanced biomarkers have established the foundation for a new era of disease-modifying treatments, prompting a strategic industry shift toward preclinical intervention and combination therapies targeting multiple pathological pathways. Concurrently, integrated care models like the GUIDE initiative are reducing hospitalizations while AI-driven diagnostics and lifestyle-based prevention strategies aim to address the critical shortage of providers for the estimated 47 million Americans with silent Alzheimer's pathology. With significant government funding increases and projected 2030 innovations in low-cost at-home monitoring, the field is rapidly evolving toward a precision prevention framework that combines pharmacological, metabolic, and digital interventions to delay cognitive decline.